February 22, 2016

Not intended for U.S. and UK Media

Bayer Receives EU Approval of Kovaltry® for Treatment of Hemophilia A

Leverkusen, February 22, 2016 - Bayer has received approval from the European
Commission of Kovaltry® for the treatment of hemophilia A in patients of all
age groups. Kovaltry is an unmodified full-length recombinant factor VIII
product, that in clinical trials has demonstrated control of bleeds, and
protection from bleeds in hemophilia A patients when used prophylactically two
or three times per week.

"This approval is the next milestone in our long-term effort to bring new and
innovative treatments to the market," said Dr. Joerg Moeller, member of the
Executive Committee of Bayer AG's Pharmaceutical Division and Head of
Development. "Bayer has a long-term commitment to the Hemophilia community and
we're excited to introduce Kovaltry as a new treatment option for patients with
hemophilia A."

"Hemophilia treatment has advanced considerably over the past decades; however,
there is more that can be done to improve patients' quality of life," said
Prof. Dr. med. Johannes Oldenburg, Chairman and Director of the Institute of
Experimental Hematology and Transfusion Medicine, University Clinic Bonn. "The
demonstrated efficacy of two and three times per week prophylactic treatment
provides the flexibility to tailor the treatment to the specific need of each
person affected by hemophilia A."

The approval was based on the LEOPOLD (Long-Term Efficacy Open-Label Program in
Severe Hemophilia A Disease) Clinical Development Program, which consisted of
three multinational clinical trials designed to evaluate the pharmacokinetics,
efficacy and safety of Kovaltry. The combined trials evaluated Kovaltry in more
than 200 children and adults with severe hemophilia A from 60 sites and 25
countries worldwide.

Bayer is pursuing regulatory approvals of Kovaltry for the treatment of
hemophilia A in many markets across the world.

The European approval of Kovaltry builds upon Bayer's growing hematology
portfolio which also includes Kogenate® Bayer, a product currently on the
market in more than 70 countries globally, as well as a long-acting recombinant
factor VIII pipeline candidate. Bayer is also pursuing alternative treatment
approaches, in preclinical and early clinical development, such as factor VIII
gene therapy and inhibition of tissue factor pathway inhibitor (TFPI), in
hemophilia, as well as in other blood disorders.

About Hemophilia

Hemophilia affects approximately 400,000 people around the world and is a
largely inherited disorder in which one of the proteins needed to form blood
clots is missing or reduced. Hemophilia A is the most common type of hemophilia
where factor VIII is missing or reduced. Hemophilia A affects 1 in 10,000
males, including more than 30,000 in Europe. Over time, hemophilia A can cause
prolonged or spontaneous bleeding, especially into the joints, muscles or
internal organs.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2014, the Group
employed around 119,000 people and had sales of EUR 42.2 billion. Capital
expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com.

?
Our online press service is just a click away: press.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma


Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.